Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab
PROVETTA
Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients
1 other identifier
observational
265
1 country
1
Brief Summary
-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
May 31, 2011
CompletedFirst Posted
Study publicly available on registry
June 2, 2011
CompletedJune 2, 2011
May 1, 2011
May 31, 2011
May 31, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression-Free Survival
Progression free survival (PFS) is defined as time from study entry until progression of disease (according to RECIST 1.1) or death from any cause. Patients who are alive without having progressed at the end of the study will be censored at their last radiological assessment
Secondary Outcomes (2)
Response Rate
Overal survival
Eligibility Criteria
Metastatic colorectal cancer patients receiving FOLFIRI plu Bevacizumab as first-line treatment
You may qualify if:
- Histologically confirmed colorectal adenocarcinoma;
- Measurable metastatic disease according to RECIST criteria;
- Patients receiving BV plus FOLFIRI as first-line treatment;
- Written informed consent;
- Availability of blood samples for genetic analysis.-
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Polo Oncologico Azienda Ospedaliero, Universitaria Pisana
Pisa, Pisa, 56126, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 31, 2011
First Posted
June 2, 2011
Study Start
April 1, 2009
Last Updated
June 2, 2011
Record last verified: 2011-05